ArticleDiagnostics (Basel, Switzerland)2024

Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study.

Erica Bonazzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.